Previous 2x2 factorial MR studies have identified combination therapies primarily within cardiovascular disease between PCSK9 and CETP inhibition, NPC1L1 and HMGCR inhibition, and IL-6 and PCSK9/CETP/NPC1L1 inhibition (8, 33, 34). This evidence concerns the gene HMGCR and cardiovascular disorder.